| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_994d1034e8cc636d2029b05fc7aa2ed2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d3b6e03a92d64f0e4893a8b297f7647 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
2000-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20745a3eabde12548dc0f4461f63dcd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7486609830c78ef28039d09059fa87f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_742f9fe3ac3c254b2cf0b9e6a509fc22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44651917ded32c7afc6136d550a89978 |
| publicationDate |
2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2371929-C |
| titleOfInvention |
Fab'-epitope complex from the hiv-1 cross-neutralizing monoclonal antibody 2f5 |
| abstract |
The crystal structure of the Fab' fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncomplexed and complexed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence. |
| priorityDate |
1999-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |